Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Papillary Renal Cell Carcinoma (Prcc)”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Study completedNCT02489695
What this trial is testing

Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma

Who this might be right for
Papillary Renal Cell Carcinoma
Centre Leon Berard 44
Testing effectiveness (Phase 2)Looking for participantsNCT05665361
What this trial is testing

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Who this might be right for
Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI) 100
Large-scale testing (Phase 3)Active Not RecruitingNCT05043090
What this trial is testing

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Who this might be right for
Papillary Renal Cell Carcinoma
AstraZeneca 148
Testing effectiveness (Phase 2)Study completedNCT02127710
What this trial is testing

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Who this might be right for
Papillary Renal Cell Cancer
AstraZeneca 111
Testing effectiveness (Phase 2)Looking for participantsNCT05096390
What this trial is testing

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Who this might be right for
Papillary Renal Cell Carcinoma Type 2
Centre Leon Berard 72
Large-scale testing (Phase 3)Active Not RecruitingNCT03091192
What this trial is testing

Savolitinib vs. Sunitinib in MET-driven PRCC.

Who this might be right for
CarcinomaCarcinoma, Renal CellKidney Neoplasms+5 more
AstraZeneca 60
Not applicableLooking for participantsNCT07024680
What this trial is testing

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

Who this might be right for
Papillary Renal Cell Carcinoma
AstraZeneca 150